AI assistant
Telix Pharmaceuticals Ltd — Share Issue/Capital Change 2024
Jun 26, 2024
31324_rns_2024-06-26_01cc3b0f-181e-4629-9928-a596a7d091f6.pdf
Share Issue/Capital Change
Open in viewerOpens in your device viewer
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities
==> picture [21 x 22] intentionally omitted <==
Announcement Summary
Entity name
TELIX PHARMACEUTICALS LIMITED
Date of this announcement
Wednesday June 26, 2024
The +securities the subject of this notification are:
+Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX Total number of +securities to be issued/transferred
| Total number of | |||
|---|---|---|---|
| ASX +security | +securities to be | ||
| code | Security description | issued/transferred | Issue date |
| TLXAO | SHARE APPRECIATION RIGHTS | 144,037 | 26/06/2024 |
Refer to next page for full details of the announcement
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities
1 / 6
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities
==> picture [21 x 22] intentionally omitted <==
Part 1 - Entity and announcement details
1.1 Name of entity
TELIX PHARMACEUTICALS LIMITED
We (the entity named above) give notice of the issue, conversion or payment up of the following unquoted +securities.
1.2 Registered number type Registration number ACN 616620369
1.3 ASX issuer code
TLX
1.4 The announcement is
New announcement
1.5 Date of this announcement
26/6/2024
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities
2 / 6
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities
==> picture [21 x 22] intentionally omitted <==
Part 2 - Issue details
2.1 The +securities the subject of this notification are:
+Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX
2.2a This notification is given in relation to an issue of +securities in a class which is not quoted on ASX and which:
has an existing ASX security code ("existing class")
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities
3 / 6
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities
==> picture [21 x 22] intentionally omitted <==
Part 3B - number and type of +securities the subject of this notification (existing class) where issue has not previously been notified to ASX in an Appendix 3B
ASX +security code and description
TLXAO : SHARE APPRECIATION RIGHTS
Date the +securities the subject of this notification were issued
26/6/2024
Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class Yes Were any of the +securities issued to +key management personnel (KMP) or an +associate? Yes Provide details of the KMP or +associates being issued +securities. Name of KMP Name of registered holder Number of +securities Christian Behrenbruch Christian Behrenbruch 144,037 Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms Refer to Telix's 2023 Remuneration Report, within the 2023 Annual Report and to Telix's 2024 Annual General Meeting Notice of Meeting for Performance Share Appreciation Rights valuation methodology, accessible at https://telixpharma.co m/investorcentre/financial-reports-presentations/ Any other information the entity wishes to provide about the +securities the subject of this notification Performance Share Appreciation Rights (notional exercise price $11.94) granted to Managing Director and Group Chief Executive Officer, Christian Behrenbruch, as part of his Target Total Remuneration Package for FY24 following shareholder approval at the Company's AGM held on 22 May 2024. Vesting is subject to achievement of performance conditions and the terms of Telix's Equity Incentive Plan Rules, with a measurement period of 2024-2026. For further details, refer to the Remuneration Report in Telix's 2023 Annual Report accessible at https://telixpharma.com/investorcent re/financial-reports-presentations/
Issue details
Number of +securities
144,037
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities
4 / 6
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities
==> picture [21 x 22] intentionally omitted <==
Part 4 - +Securities on issue
Following the issue, conversion or payment up of the +securities the subject of this notification, the +securities of the entity will comprise:
The figures in parts 4.1 and 4.2 below are automatically generated and may not reflect the entity's current issued capital if other Appendix 2A, Appendix 3G or Appendix 3H forms are currently with ASX for processing.
4.1 Quoted +securities (Total number of each +class of +securities issued and quoted on ASX)
| Total number of | |
|---|---|
| ASX +security code and description | +securities on issue |
| TLX : ORDINARY FULLY PAID | 334,126,898 |
| 4.2 Unquoted +securities (Total number of each +class of +securities issued but not quoted on ASX) | |
| Total number of | |
| ASX +security code and description | +securities on issue |
| TLXAQ : SHARE RIGHTS EXPIRING 13-JUN-2027 EX NIL | 80,000 |
| TLXAR : PERFORMANCE RIGHTS | 6,807,720 |
| TLXAP : SHARE RIGHTS | 1,230,000 |
| TLXAO : SHARE APPRECIATION RIGHTS | 11,356,817 |
| TLXAM : OPTION EXPIRING 20-JUL-2026 EX $5.37 | 584,492 |
| TLXAN : SHARE RIGHTS EXPIRING 20-JUL-2026 EX NIL | 100,000 |
| TLXAL : OPTION EXPIRING 27-JAN-2026 EX $4.38 | 685,510 |
| TLXAS : PERFORMANCE SHARE INCENTIVE RIGHTS | 440,000 |
4.2 Unquoted +securities (Total number of each +class of +securities issued but not quoted on ASX)
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities
5 / 6
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities
==> picture [21 x 22] intentionally omitted <==
Part 5 - Other Listing Rule requirements
5.1 Were the +securities issued under an exception in Listing Rule 7.2 and therefore the issue did not need any security holder approval under Listing Rule 7.1? Yes
5.1a Select the number of the applicable exception in Listing Rule 7.2
14
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities
6 / 6